Satoshi Morita

Publications (174)588.41 Total impact

• Article: Preoperative Chemotherapy Is Effective for Stage III Resectable Non-Small-Cell Lung Cancer: Metaanalysis of 16 Trials.

  Nobuyuki Horita, Naoki Miyazawa, Satoshi Morita, Ryota Kojima, Naoko Kimura, Takeshi Kaneko, Yoshiaki Ishigatsubo
  [show abstract] [hide abstract]
  ABSTRACT: BACKGROUND: The benefit of preoperative chemotherapy for resectable non-small-cell lung cancer is still controversial. PATIENTS AND METHODS: We conducted fixed-model metaanalysis including randomized controlled trials comparing 'preoperative chemotherapy plus surgery' and 'surgery alone' as a primary study with sufficient data to provide a hazard ratio for overall survival. MEDLINE and Cochrane databases were used for the study search. RESULTS: We found 16 studies. Seven included only stage III disease cases, and 9 were conducted without stage limitation. Sixteen trials involving 3728 samples observing 2326 deaths yielded a pooled hazard ratio for overall survival of 0.84 (95% confidence interval [CI], 0.77-0.91; P < .001) with moderate heterogeneity (I(2) = 40%). In sensitivity analysis, strong heterogeneity (I(2) = 69%) was found between the 7 trials covering only stage III disease and 9 trials without stage limitation. The 7 studies evaluating only stage III disease involving 1447 samples and 1068 deaths yielded a pooled hazard ratio of 0.77 (95% CI, 0.68-0.87; P < .001) with nonsignificant low heterogeneity (I(2) = 17%). No publication bias was observed throughout this study. The effect of preoperative chemotherapy differs among stages. The pooled hazard ratio comparing 'preoperative chemotherapy plus surgery' and 'surgery alone' for patients with stage III disease in our study was 0.77, which is slightly better than the pooled hazard ratio of 0.83 in the Lung Adjuvant Cisplatin Evaluation study that compared 'surgery plus postoperative chemotherapy' and 'surgery alone.' CONCLUSION: Preoperative chemotherapy plus surgery for stage III disease is more effective than previously considered.
  Clinical Lung Cancer 05/2013; · 2.94 Impact Factor
• Article: Antithrombotic drugs are risk factors for delayed postoperative bleeding after endoscopic submucosal dissection for gastric neoplasms.

  Ryonho Koh, Kingo Hirasawa, Sei Yahara, Hiroyuki Oka, Kazuya Sugimori, Manabu Morimoto, Kazushi Numata, Atsushi Kokawa, Takeshi Sasaki, Akinori Nozawa, Masataka Taguri, Satoshi Morita, Shin Maeda, Katsuaki Tanaka
  [show abstract] [hide abstract]
  ABSTRACT: BACKGROUND: The discontinuation of antithrombotic drugs is recommended during endoscopic submucosal dissection (ESD) for gastric neoplasms; however, controversy remains as to whether antithrombotic drugs are risk factors for postoperative bleeding. OBJECTIVE: To determine the risk factors for post-ESD bleeding. DESIGN: Single-institution, retrospective review. SETTING: University hospital. PATIENTS: From June 2000 to December 2010, we treated 1192 gastric neoplasms in 1032 consecutive patients. INTERVENTION: The ESD procedures were performed by using the standard techniques. Antithrombotic drug therapy was principally interrupted preoperatively and was restarted when hemostasis was confirmed by second-look endoscopy. MAIN OUTCOME MEASUREMENTS: Risk factors for postoperative bleeding after ESD (early, delayed, and overall [combined] occurrence of bleeding during the first 5 postoperative days or thereafter) were analyzed by using logistic regression analysis. RESULTS: Among 1166 ESD-induced ulcer lesions, overall postoperative bleeding was evident in 62 lesions (5.3%); early and delayed bleeding occurred in 30 and 32 lesions (2.6% and 2.7%), respectively. Based on a multivariate analysis, a specimen size of >40 mm was the sole independent risk factor for overall bleeding. Moreover, oral antithrombotic drug therapy was selected as independent risk factor for delayed but not early bleeding, according to the multivariate analysis. The delayed bleeding rate in patients who had a specimen size of >40 mm and who used antithrombotic drugs was 11.6%. LIMITATIONS: Retrospective design and single-site data collection. CONCLUSION: Interruption of antithrombotic drug therapy may be adequate for preventing early post-ESD bleeding; however, reinitiating antithrombotic drug therapy is a significant independent risk factor for delayed post-ESD bleeding.
  Gastrointestinal endoscopy 04/2013; · 6.71 Impact Factor
• Article: Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer.

  Yoshiko Urata, Isamu Okamoto, Masayuki Takeda, Yoshihiro Hattori, Keiko Okuno, Temiko Shimada, Takayasu Kurata, Hiroyasu Kaneda, Masaki Miyazaki, Masaaki Terashima, Kaoru Tanaka, Satoshi Morita, Kazuhiko Nakagawa, Shunichi Negoro, Miyako Satouchi
  [show abstract] [hide abstract]
  ABSTRACT: BACKGROUND: A previous phase 3 trial demonstrated noninferiority in terms of overall survival for combined S-1 (an oral fluoropyrimidine) and carboplatin compared with combined paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). In the current study, the authors evaluated the efficacy and safety of combined S-1, carboplatin, and bevacizumab followed by maintenance with S-1 and bevacizumab in chemotherapy-naive patients with advanced nonsquamous NSCLC. METHODS: Patients received carboplatin (area under the concentration-time curve, 5 mg mL(-1) per minute) and bevacizumab (15 mg/kg) on day 1 plus oral S-1 (80 mg/m(2) per day) on days 1 through 14 every 21 days for up to 6 cycles. For patients without disease progression, S-1 and bevacizumab were continued until disease progression or unacceptable toxicity developed. RESULTS: Forty-eight patients were enrolled in the phase 2 study; of these, 35 patients (72.9%) completed at least 4 cycles. Most toxicities of grade ≥3 were hematologic, and no increase in relative incidence associated with maintenance with S-1 and bevacizumab was observed. The objective response rate was 54.2% (95% confidence interval, 39.2%-68.6%), and the median progression-free survival was 6.8 months (95% confidence interval, 4.3-8.2 months). CONCLUSIONS: The regimen of combined S-1, carboplatin, and bevacizumab followed by maintenance with S-1 and bevacizumab was active and feasible as first-line treatment for advanced nonsquamous NSCLC. Cancer 2013. © 2013 American Cancer Society.
  Cancer 04/2013; · 4.77 Impact Factor
• Article: Risk Factors for Severe Adverse Effects and Treatment-related Deaths in Japanese Patients Treated with Irinotecan-based Chemotherapy: A Postmarketing Survey.

  Tomoo Shiozawa, Jun-Ichi Tadokoro, Toshitaka Fujiki, Koji Fujino, Koji Kakihata, Shuji Masatani, Satoshi Morita, Akihiko Gemma, Narikazu Boku
  [show abstract] [hide abstract]
  ABSTRACT: OBJECTIVES: This analysis was conducted to clarify risk factors for severe adverse effects and treatment-related deaths reported during a postmarketing survey of irinotecan. METHODS: The survey covered all patients treated with irinotecan in Japan between April 1995 and January 2000. The patient background data and adverse drug reactions were collected through case report forms. Univariate and multivariate logistic regression analyses including 14 explanatory variables were performed to determine the risk factors for grade 3-4 leukopenia, thrombocytopenia and diarrhea for all patients and subgroups with five major cancers. Treatment-related deaths were also analyzed. RESULTS: Case report forms of 13 935 patients (94.1% of 14 802 patients registered) treated with irinotecan-based chemotherapy were collected. Major grade 3-4 adverse drug reactions were leukopenia (34.8%), thrombocytopenia (12.4%) and diarrhea (10.1%). Multivariate analysis revealed that the risk factors (odds ratio ≥1.5) common for all these three adverse drug reactions were performance status (≥3), infection and renal dysfunction before starting irinotecan therapy. Additionally, the risk factors for leukopenia were being female and prior radiotherapy, those for thrombocytopenia were age (≥65 years), while those for diarrhea were pleural effusion and watery stool. The risk factors in each cancer were also identified. The incidence of treatment-related death was 1.3% (176). Myelosuppression-related deaths accounted for 70% and interstitial lung disease for 11% of all treatment-related deaths. Being male, age, performance status ≥3, massive ascites and infection and renal dysfunction were identified as risk factors for treatment-related death. CONCLUSIONS: To ensure the safety of irinotecan therapy, it is important to select appropriate patients by considering the risk factors.
  Japanese Journal of Clinical Oncology 03/2013; · 1.78 Impact Factor
• Article: Association Between Gait Speed as a Measure of Frailty and Risk of Cardiovascular Events Following Myocardial Infarction.

  Yasushi Matsuzawa, Masaaki Konishi, Eiichi Akiyama, Hiroyuki Suzuki, Naoki Nakayama, Masayoshi Kiyokuni, Shinichi Sumita, Toshiaki Ebina, Masami Kosuge, Kiyoshi Hibi, [......], Kenichiro Saka, Katsutaka Hashiba, Kozo Okada, Masataka Taguri, Satoshi Morita, Seigo Sugiyama, Hisao Ogawa, Hironobu Sashika, Satoshi Umemura, Kazuo Kimura
  [show abstract] [hide abstract]
  ABSTRACT: OBJECTIVES: This study was designed to determine the additional clinical value of gait speed to Framingham risk score (FRS), cardiac function and comorbid conditions in predicting cardiovascular events in patients with ST-segment-elevation myocardial infarction (STEMI). BACKGROUND: There is growing evidence that gait speed is inversely associated with all-causes mortality, particularly cardiovascular mortality, among the elderly. METHODS: We undertook a single-center prospective observational study of gait speed in 472 patients with STEMI in Japan, between 2001 and 2008. Gait speeds were measured using 200-meter course before discharge in all patients and we followed cardiovascular events which consist of cardiovascular deaths, non-fatal myocardial infarctions, and non-fatal ischemic strokes. RESULTS: During the 2596 person-years of follow-up, 83 patients (17.6%) experienced cardiovascular events. Cardiovascular events increased across decreasing tertiles of gait speed (fastest tertile: n=5; 3.2%, middle tertile: n=20; 12.6%, slowest tertile: n=58; 36.7%). By multiple adjusted Cox proportional hazards analysis, gait speed was a significant and independent predictor of cardiovascular events (hazard ratio for increasing 0.1m/s of gait speed: 0.71, 95% confidence interval [CI]: 0.63 - 0.81, P<0.001). The addition of gait speed to the model incorporating FRS, B-type natriuretic peptide levels and comorbidity index improved reclassification (Net reclassification index: 32.8%, 95% CI: 17.4 - 48.3, P<0.001) and the C-statistics with a reasonable global fit and calibration (C-statistics [95% CI]: from 0.703 [0.636 - 0.763] to 0.786 [0.738 - 0.829]). CONCLUSION: Among patients with STEMI, slow gait speed was significantly associated with an increased risk of cardiovascular events.
  Journal of the American College of Cardiology 03/2013; · 14.16 Impact Factor
• Article: INTERNAL LIMITING MEMBRANE CONTRAST AFTER STAINING WITH INDOCYANINE GREEN AND BRILLIANT BLUE G DURING MACULAR SURGERY.

  Kazuaki Kadonosono, Akira Arakawa, Maiko Inoue, Shin Yamane, Eiichi Uchio, Tadashi Yamakawa, Masataka Taguri, Satoshi Morita, Jamison R Ridgeley, Yasuo Yanagi
  [show abstract] [hide abstract]
  ABSTRACT: PURPOSE:: To evaluate the difference in color contrast by performing a color contrast ratio (CR) analysis and resulting visibility of the internal limiting membrane (ILM) when stained with indocyanine green and brilliant blue G (BBG) during macular surgery by performing a color CR analysis. METHODS:: The authors analyzed 40 consecutive cases in which vitrectomy with ILM removal was performed to treat a macular hole or an epiretinal membrane. The surgical procedure was performed in 21 patients (21 eyes) after staining with indocyanine green and in 19 patients (19 eyes) after staining with BBG. The color CRs were estimated based on digital analysis of the red, green, and blue data of the digital images captured, and the CRs obtained with the two dyes were compared. RESULTS:: Color contrast analysis was performed in all 40 eyes, in which the ILM was removed after staining with indocyanine green or BBG, and the CRs were estimated in every eye. The CR (mean ± SD) obtained with indocyanine green and BBG was 4.3 ± 0.3 and 2.4 ± 0.1, respectively. Indocyanine green provided a significantly higher CR than BBG (P = 0.015). CONCLUSION:: Digital color contrast analysis can be used to evaluate the visibility of digital images, and it may be useful when choosing the dye to use for staining the ILM better.
  Retina (Philadelphia, Pa.) 03/2013; · 2.93 Impact Factor
• Article: High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival.

  Akimitsu Yamada, Takashi Ishikawa, Ikuko Ota, Mariko Kimura, Daisuke Shimizu, Mikiko Tanabe, Takashi Chishima, Takeshi Sasaki, Yasushi Ichikawa, Satoshi Morita, Koh-Ichiro Yoshiura, Kazuaki Takabe, Itaru Endo
  [show abstract] [hide abstract]
  ABSTRACT: ATP-binding cassette (ABC) transporters are membrane proteins that efflux various compounds from cells, including chemotherapeutic agents, and are known to affect multidrug resistance. Recent reports disagree on whether ABCC11 is a risk factor for breast tumorigenesis, but its expression in breast cancer is poorly investigated. We hypothesized that both frequency and expression levels of ABC transporters in breast tumors would vary by cancer subtype, and be associated with prognosis. Here, we constructed a tissue microarray breast tumor samples from 281 patients, and analyzed expressions of ABCB1, ABCC1, ABCC11, and ABCG2 immunohistochemically. Breast cancer subtypes were determined by immunohistochemistry of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2). Protein expression was correlated to clinicopathological characteristics, clinical follow-up, and pathological complete response to neoadjuvant chemotherapy. The tissue microarray comprised 191 luminal A (68.0 %), 17 luminal B (6.0 %), 27 HER2 (9.6 %), and 46 triple-negative (16.4 %) samples. ABCC1 and ABCC11 expressions were associated with significantly shorter disease-free survival (P = 0.027 and P = 0.003, respectively). ABCC1, ABCC11, and ABCG2, but not ABCB1, were expressed significantly more, and more frequently, in aggressive subtypes. Patients with HER2+ and triple-negative tumor subtypes that expressed high levels of ABCC11 had significantly worse disease-free survival (P = 0.017 and P < 0.001, respectively). We have shown, for the first time, that ABCC1, ABCC11, and ABCG2 are highly expressed in aggressive breast cancer subtypes, and that tumor ABCC11 expression is associated with poor prognosis.
  Breast Cancer Research and Treatment 01/2013; · 4.43 Impact Factor
• Article: Anemia affects the quality of life of Japanese cancer patients.

  Izumi Wasada, Hisae Eguchi, Maya Kurita, Shitomi Kudo, Tomoko Shishida, Yaeko Mishima, Yuko Saito, Nobuko Ushiorozawa, Takashi Seto, Kojiro Shimozuma, Satoshi Morita, Mari Saito, Yuki Yokomizo, Kenichi Ishizawa, Yasuo Ohashi, Kenji Eguchi
  [show abstract] [hide abstract]
  ABSTRACT: The Functional Assessment of Cancer Therapy-Anemia (FACT-An) was developed to measure the effect of anemia on quality of life (QOL) in cancer patients. We have previously validated the Japanese version of the FACT-An in Japanese cancer patients receiving chemotherapy, hormone therapy, or radiation therapy. That analysis was limited to evaluating the relationship between QOL scores and hemoglobin (Hb) levels. In this study, the data were further analyzed in order to identify factors that affect QOL. The mean Hb level of the patients was unchanged over three months. Patient age, Eastern Oncology Group Performance Status (ECOG-PS) score, Hb level, and the type of treatment method received were each predictive factors of a patient's FACT-An score at baseline, while the patient's Hb level at three months and whether the patient had received a blood transfusion were both predictive factors of a patient's FACT-An score at three months. Anemia consistently negatively affected the QOL of cancer patients measured over a three-month period. These results confirm the clinical effectiveness of the FACT-An as a tool to assess anemia-related QOL in Japanese cancer patients.
  The Tokai journal of experimental and clinical medicine 01/2013; 38(1):7-11.
• Article: Basal and ischemia-induced transcardiac troponin release into the coronary circulation in patients with suspected coronary artery disease.

  Masaaki Konishi, Seigo Sugiyama, Koichi Sugamura, Toshimitsu Nozaki, Keisuke Ohba, Junichi Matsubara, Kenji Sakamoto, Yasuhiro Nagayoshi, Hitoshi Sumida, Eiichi Akiyama, Yasushi Matsuzawa, Kentaro Sakamaki, Satoshi Morita, Kazuo Kimura, Satoshi Umemura, Hisao Ogawa
  [show abstract] [hide abstract]
  ABSTRACT: Cardiac troponin is a specific biomarker for cardiomyocyte necrosis in acute coronary syndromes. Troponin release from the coronary circulation remains to be determined because of the lower sensitivity of the conventional assay. We sought to determine basal and angina-induced troponin release using a highly sensitive troponin assay. The cardiac troponin T levels in serum sampled from the peripheral vein (PV), the aortic root (AO), and the coronary sinus (CS) were measured in 105 consecutive stable patients with coronary risk factor(s) and suspected coronary artery disease (CAD) and in 33 patients without CAD who underwent an acetylcholine provocation test. At baseline, there was a significant increase in the troponin levels from AO [9.0 (6.4, 13.1) pg/mL for median (25(th), 75(th) percentiles)] to CS [10.3 (7.3, 15.5) pg/mL, p<0.001] in 96 (91.4%) patients and the difference was 1.1 (0.4, 2.1) pg/mL, which reflected basal transcardiac troponin release (TTR). TTR was positively correlated with PV levels (r = 0.22, p = 0.03). Male sex, left ventricular hypertrophy determined by echocardiography, T-wave inversion, and CAD correlated with elevated TTR defined as above: median, 1.1 pg/mL. A significant increase in TTR was noted in 17 patients with coronary spasms [0.6 (0.2, 1.2) pg/mL, p<0.01] but not in 16 patients without spasms [0.0 (-0.5, 0.9) pg/mL, p = 0.73] after the acetylcholine provocation. Basal TTR in the coronary circulation was observed in most of the patients with suspected CAD and risk factor(s). This sensitive assay detected myocardial ischemia-induced increases in TTR caused by coronary spasms.
  PLoS ONE 01/2013; 8(4):e60163. · 4.09 Impact Factor
• Article: The superiority of the seventh edition of the TNM classification depends on the overall survival of the patient cohort: Comparative analysis of the sixth and seventh TNM editions in patients with gastric cancer from Japan and the United Kingdom.

  Tsutomu Hayashi, Takaki Yoshikawa, Kiran Bonam, Henry M Sue-Ling, Masataka Taguri, Satoshi Morita, Akira Tsuburaya, Jeremy D Hayden, Heike I Grabsch
  [show abstract] [hide abstract]
  ABSTRACT: BACKGROUND: The objective of this study was to investigate whether the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer TNM classification (TNM7) had superior discriminatory ability over the sixth edition of the TNM classification (TNM6) in patients with gastric cancer regardless of their country of origin. METHODS: In total, 538 patients from the Kanagawa Cancer Center Hospital (Yokohama, Japan) (KCCH) and 519 patients from the Leeds Teaching Hospitals National Health Service Trust (Leeds, United Kingdom) (LTHT) who underwent surgery for gastric cancer were selected. Overall survival was used for statistical analysis. Hazard ratios (HRs) were estimated with disease stage as a continuous variable to evaluate the discriminatory ability of the TNM stage groups. The estimates of log HRs (logHRs) for the TNM6 and the TNM7 stage groups were compared. RESULTS: In the KCCH cohort, 82 patients (15%) were upstaged, and 26 patients (5%) were downstaged between TNM6 and TNM7 compared with 253 patients (49%) and 53 patients (10%), respectively, in the LTHT cohort. The logHRs for a 1-stage increase within TNM6 and TNM7 were 1.06 and 1.16, respectively, in the KCCH cohort and 0.57 and 0.79, respectively, in the LTHT cohort. The differences in logHRs between TNM6 and TNM7 were significant in each cohort (KCCH: logHR, 0.11; P = .024; LTHT: logHR, 0.21; P = .0002) and between the 2 cohorts. CONCLUSIONS: TNM7 had superior discriminatory ability compared with TNM6 in both cohorts. The improved ability to discriminate patients with different survival probability when using TNM7 was greater in the LTHT cohort. The current findings indicated that the discriminatory ability of the TNM stage groups may depend on the baseline survival characteristics of the patient cohort. Cancer 2013. © 2013 American Cancer Society.
  Cancer 12/2012; · 4.77 Impact Factor
• Article: A Randomized Phase II Trial of Omentum-preserving Gastrectomy for Advanced Gastric Cancer.

  Shinichi Hasegawa, Yuji Yamamoto, Masataka Taguri, Satoshi Morita, Tsutomu Sato, Roppei Yamada, Takashi Oshima, Norio Yukawa, Takaki Yoshikawa, Yasushi Rino, Toshio Imada, Munetaka Masuda
  [show abstract] [hide abstract]
  ABSTRACT: This randomized Phase II trial is being conducted to evaluate the impact of omentectomy for advanced gastric cancer on patient survival. The primary endpoint is the 3-year relapse-free survival rate and the secondary endpoints are 5-year overall survival, intraoperative blood loss, length of the operation and postoperative morbidity (especially postoperative ileus). The planned sample size is 250 patients (125 for complete removal of the omentum and 125 for preservation of the omentum) to determine whether omentum-preserving gastrectomy may be a candidate procedure for a Phase III trial in a randomized Phase II setting.
  Japanese Journal of Clinical Oncology 12/2012; · 1.78 Impact Factor
• Article: Effects of IL-28B gene polymorphism on response to peginterferon plus ribavirin combination therapy for genotype 2 chronic hepatitis C.

  Yu Shimoyama, Akito Nozaki, Manabu Morimoto, Satoshi Moriya, Masaaki Kondo, Hiroyuki Fukuda, Kazushi Numata, Eiji Miyajima, Mari S Oba, Masataka Taguri, Satoshi Morita, Shin Maeda, Katsuaki Tanaka
  [show abstract] [hide abstract]
  ABSTRACT: AIM: Interleukin (IL)-28B gene polymorphism is closely linked with treatment response to peginterferon plus ribavirin combination therapy for hepatitis C virus genotype 1. However, few studies have reported its effects on therapy for genotype 2. We aimed to examine the effects of IL-28B gene polymorphism on treatment response in hepatitis C virus genotype 2 patients. METHODS: In a retrospective study of 101 patients infected with either genotype 2a (n = 65) or 2b (n = 36) and treated with peginterferon plus ribavirin, we investigated predictive factors for a sustained virological response (SVR), including genetic variations near the IL-28B gene (rs8099917, rs11881222 and rs8103142) and clinical variables such as age, sex, body mass index, stage of fibrosis and drug adherence. RESULTS: Ultra-rapid virological response, rapid virological response (RVR), end-of-treatment response, SVR and relapse rates were 22.2%, 61.4%, 95.0%, 87.1% and 7.9%, respectively. In univariate analysis, RVR and IL-28B single nucleotide polymorphisms (SNP) (rs8099917, rs11881222 and rs8103142) were significantly associated with SVR. In subgroup analysis, IL-28B SNP were significantly associated with SVR in genotype 2a patients but not in genotype 2b patients. In multiple logistic regression analysis, RVR and IL-28B SNP (rs8099917) were independently associated with SVR. Furthermore, IL-28B SNP was significantly associated with relapse but RVR was not. CONCLUSION: In genotype 2 patients treated with peginterferon plus ribavirin combination therapy, IL-28B gene polymorphism was a significant independent predictor of SVR as well as RVR. IL-28B major allele may favor reduced relapse rates in patients with genotype 2 chronic hepatitis C.
  Hepatology Research 12/2012; · 2.20 Impact Factor
• Article: Depression in Japanese Patients with Chronic Obstructive Pulmonary Disease. A Cross-Sectional Study.

  Nobuyuki Horita, Takeshi Kaneko, Masaharu Shinkai, Makiko Yomota, Satoshi Morita, Bruce K Rubin, Yoshiaki Ishigatsubo
  [show abstract] [hide abstract]
  ABSTRACT: BACKGROUND: Some investigation revealed the association between depression and physical measurements of chronic obstructive pulmonary disease (COPD) patients in North America and Europe but limited studies in Asia were performed. METHODS: In this cross-sectional study, consecutive 84 stable outpatients with COPD (Age: 72.0 ± 9.0. Forced expiratory volume in one second (%predicted) 46 ± 15%. Fifteen females (17.9%)) in a Japanese community based hospital were recruited. "Probable depression" was defined as short form of the geriatric depression scale (SF-GDS) ≥ 6. Relationships among commonly used physical measurements, SF-GDS raw score, and probable depression were evaluated with Spearman's rank correlation test, multiple linear regression analysis, logistic regression analysis, and receiver operating characteristic curve. RESULTS: Thirty two (38.1%) had probable depression. Body mass index, obstruction, dyspnea, exercise capacity index; forced expiratory volume in one second (%predicted); modified medical research council dyspnea scale; six-minute walk distance; saturation of oxygen on artery by pulse oximetry had followings: (i) simple correlations (|r|:0.42 0.60 , P < .001 for all) for SF GDS raw score, (ii) partial correlations (|r|:0.25 0.51 , P < .05 for all) for SF GDS raw score after adjusting demographic and social factors, (iii) association for probable depression in logistic regression analysis after adjusting demographic and social factors (P < .05 for all), and (iv) area under the receiver operating characteristic curves for probable depression (area under the curves: 0.719-0.841, P < .001 for any), CONCLUSIONS: Physical parameters were associated with depression in our Japanese COPD outpatients.
  Respiratory care 12/2012; · 2.01 Impact Factor
• Article: WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial.

  Takashi Miyatake, Yutaka Ueda, Akiko Morimoto, Takayuki Enomoto, Sumiyuki Nishida, Toshiaki Shirakata, Yoshihiro Oka, Akihiro Tsuboi, Yusuke Oji, Naoki Hosen, Shin-Ichi Nakatsuka, Satoshi Morita, Junichi Sakamoto, Haruo Sugiyama, Tadashi Kimura
  [show abstract] [hide abstract]
  ABSTRACT: OBJECTIVE: The aim of the present study was to analyze the long-term survival effects of WT1 peptide vaccine, in addition to its anti-tumor effects and toxicity. METHODS: A phase II clinical trial was conducted during the period of 2004-2010 at Osaka University Hospital, Osaka, Japan. The patients who had gynecologic malignancies progressing against previous treatments received WT1 peptide vaccine intradermally at 1-week intervals for 12 weeks. The vaccination was allowed to further continue, unless the patient's condition became significantly worse due to the disease progression. RESULTS: Forty out of 42 patients, who met all the inclusion criteria, underwent WT1 peptide vaccine. Among these 40 patients, stable disease was observed in 16 cases (40 %). Skin toxicity of a grade 1, 2 and 3 occurred in 25 cases (63 %), 9 cases (23 %) and a single case (3 %), respectively, and liver toxicity of grade 1 in a single case (3 %). The overall survival period was significantly longer in cases positive for the WT1 peptide-specific delayed-type hypersensitivity (DTH) reaction after the vaccination, compared to those negative for the DTH reaction (p = 0.023). Multivariate Cox proportional hazards analysis demonstrated that the adjusted hazard ratio for the negative DTH reaction was 2.73 (95 % CI 1.04-7.19, p = 0.043). CONCLUSION: WT1 peptide vaccine may be a potential treatment, with limited toxicity, for gynecologic malignancies that have become resistant to conventional therapies. Larger scale of clinical studies is required to establish the efficacy of the WT1 peptide vaccine for gynecologic malignancies.
  Journal of Cancer Research and Clinical Oncology 11/2012; · 2.56 Impact Factor
• Article: Postprogression Survival in Patients With Advanced Non-Small-Cell Lung Cancer Who Receive Second-Line or Third-Line Chemotherapy.

  Hidetoshi Hayashi, Isamu Okamoto, Masataka Taguri, Satoshi Morita, Kazuhiko Nakagawa
  [show abstract] [hide abstract]
  ABSTRACT: BACKGROUND: The increased availability of active agents has improved overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC). We previously showed that postprogression survival (PPS) is highly associated with OS in the first-line setting, but little is known about PPS in the salvage setting. In this study, we analyzed PPS in phase III trials in the second-line or third-line setting. PATIENTS AND METHODS: A literature search identified 18 trials for previously treated patients with advanced NSCLC. We partitioned OS into progression-free survival (PFS) and PPS and evaluated the association between OS and either PFS or PPS. Correlation analysis to examine whether a treatment benefit for PFS carried over to OS was performed by calculation of incremental gains in OS and PFS at the trial level. RESULTS: The average median PPS was longer than the average median PFS (5.4 and 2.6 months, respectively). The induction rate for subsequent chemotherapy after second-line or third-line treatment was related to the duration of PPS in linear regression analysis (r(2) = 0.4813). Median OS was highly associated with median PPS but not with PFS (r = 0.94 and 0.51, respectively), and only a weak association between the treatment benefits for PFS and OS was detected (r = 0.29). CONCLUSIONS: Treatment benefit for OS in patients with advanced NSCLC can be skewed by the effects of subsequent therapies in the second-line or third-line setting. Whether PFS or OS is the more appropriate endpoint for trials in the salvage setting should be considered.
  Clinical Lung Cancer 10/2012; · 2.94 Impact Factor
• Article: Radiofrequency ablation combined with transarterial chemoembolization for subcapsular hepatocellular carcinoma: A prospective cohort study.

  Manabu Morimoto, Kazushi Numata, Masaaki Kondo, Satoshi Moriya, Satoshi Morita, Shin Maeda, Katsuaki Tanaka
  [show abstract] [hide abstract]
  ABSTRACT: OBJECTIVE: This study evaluated the safety and efficacy of using radiofrequency ablation combined with transarterial chemoembolization to treat hepatocellular carcinoma in a subcapsular location, given the increased risk of complications when using radiofrequency ablation alone. MATERIALS AND METHODS: From January 2000 to December 2011, 1213 patients with unresectable hepatocellular carcinoma (up to three nodules) were screened. Of these, 132 patients with 132 subcapsular nodules (mean size, 3.0cm; range, 1.2-5.0cm) were enrolled in the study. After transarterial chemoembolization, percutaneous radiofrequency ablation was performed under ultrasound or C-arm cone-beam computed tomography guidance, on the same day or within 3 days. Local recurrence and survival curves were obtained using the Kaplan-Meier method. RESULTS: Technical success of treatment was achieved in 130 patients (98.5%). Major complications, including pleural effusion, secondary peritonitis, and liver abscess, occurred in 3 patients (2.3%); the incidence of complications was associated with the number of needle insertions (1-2 vs. 3-4, P=0.039, Fisher's exact test). No patients developed permanent sequelae, tumor seeding, or tumor bleeding. The 3-year local recurrence rate was 9.7%. Local recurrence was associated with the pretreatment serum des-gamma-carboxy prothrombin level (≤200mAU/mL vs. >200mAU/mL, P=0.019, log-rank test). The 3-, 5-, and 7-year overall survival rates in treatment-naïve cases (n=82) were 79.3%, 60.6%, and 50.9%, respectively. CONCLUSION: Combination therapy using radiofrequency ablation and transarterial chemoembolization was a safe and useful therapeutic option for patients with subcapsular hepatocellular carcinoma.
  European journal of radiology 10/2012; · 2.65 Impact Factor
• Article: Omentum-preserving gastrectomy for advanced gastric cancer: a propensity-matched retrospective cohort study.

  Shinichi Hasegawa, Chikara Kunisaki, Hidetaka Ono, Takashi Oshima, Shoichi Fujii, Masataka Taguri, Satoshi Morita, Tsutomu Sato, Roppei Yamada, Norio Yukawa, Yasushi Rino, Munetaka Masuda
  [show abstract] [hide abstract]
  ABSTRACT: BACKGROUND AND OBJECTIVES: We clarified the impact of omentectomy for advanced gastric cancer on patient survival from the surgical results of a high-volume center in Japan. METHODS: Patients who received curative gastrectomy were divided into two groups based on whether they underwent omentectomy. The propensity score-matching method was used to assemble a well-balanced cohort, and relapse-free survival and the pattern of recurrence were compared. RESULTS: For this study, 330 patients who fulfilled the inclusion criteria participated and were divided into two groups: group R, patients who received omentectomy, and group P, patients who received omentum-preserving gastrectomy. After performing score-matching, 196 patients were selected. The 3- and 5-year relapse-free survival rates were 72.9 % (95 % confidence interval, 64.1-81.7) and 66.2 % (56.6-75.8 %) in group R, and 76.7 % (67.9-81.2) and 67.3 % (55.1-79.5) in group P, which were not significantly different (P = 0.750). Regarding sites of relapses, no differences were observed between the groups (P = 0.863). CONCLUSIONS: In this series, omentum-preserving gastrectomy for advanced gastric cancer did not increase the peritoneal relapse rate or affect patient survival compared to conventional gastrectomy. The non-inferiority of the omission of omentectomy should be evaluated by a randomized controlled trial.
  Gastric Cancer 09/2012; · 2.42 Impact Factor
• Article: A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II).

  Akira Tsuburaya, Satoshi Morita, Yasuhiro Kodera, Michiya Kobayashi, Kohei Shitara, Kensei Yamaguchi, Takaki Yoshikawa, Kazuhiro Yoshida, Shigefumi Yoshino, Jun-Ichi Sakamoto
  [show abstract] [hide abstract]
  ABSTRACT: BACKGROUND: On the basis of international clinical trials, capecitabine plus cisplatin (XP) as a first-line treatment of advanced gastric cancer is considered a global standard regimen. However, the usefulness of XP as compared with S-1 plus cisplatin (SP), which is considered standard therapy in Japan, has not yet been assessed. METHODS: This is a multicenter randomized phase II trial to elucidate the efficacy of XP as compared with SP for first-line treatment of advanced gastric cancer. Patients with unresectable metastatic or recurrent gastric cancer, 20-74 years of age and human epidermal growth factor 2 (HER2)-negative status, will be assigned in a 1:1 ratio to receive either S-1 40mg/m2 bid for 21days plus cisplatin 60 mg/m2 (day 8) every 5-week cycle or capecitabine 1000mg/m2 bid for 14days plus cisplatin 80 mg/m2 (day 1) every 3-week cycle. Patients will be also asked to the analysis of tumor tissues for translational investigations. The Primary endpoint is progression-free survival and secondary endpoints are overall survival, time to treatment failure, tumor response rate and safety. These comparisons will also be evaluated in terms of biomarkers. Planned sample size is 100 (50 in each arm), which is appropriate for this trial. DISCUSSION: Fluoropyrimidine plus cisplatin combination is the standard regimen of the first line treatment for advanced gastric cancer. Both S-1 and capecitabine are the prodrug of 5-FU but differ from their process of metabolism. Result of this trial and translational research will provide the important clues to prepare the individualized therapy for advanced gastric cancer in the near future. Trial Registration: ClinicalTrials.gov Identifier NCT01406249.
  BMC Cancer 07/2012; 12(1):307. · 3.01 Impact Factor
• Article: Long-term quality of life of donors after living donor liver transplantation.

  Yasutsugu Takada, Yoshimi Suzukamo, Fumitaka Oike, Hiroto Egawa, Satoshi Morita, Shunichi Fukuhara, Shinji Uemoto, Koichi Tanaka
  [show abstract] [hide abstract]
  ABSTRACT: The aim of the present study was to investigate the long-term effects of living donor liver transplantation (LDLT) on donor health-related quality of life (HRQOL) using the Short-Form Health Survey (SF-36), and to determine risk factors for poor outcomes. Between June 1990 and June 2004, 1,000 cases of LDLT were performed at Kyoto University Hospital. In July 2005, 997 of the 1,000 donors were contacted by mail to collect data on their HRQOL. A total of 578 donors responded (58% response rate). The norm-based HRQOL scores for donors were better than the Japanese norm across all time periods. All scores were similar between left- (n = 367) and right-lobe donors (n = 211). For all donors, multivariate logistic regression analysis revealed that age, "months until recovery to preoperative health status", "hospital visit due to donation-related symptoms", "rest from work in immediate past one month due to donation-related causes", and "existence of two or more co-morbidities" were significantly associated with decreased HRQOL scores. Postoperative complications or recipient mortality were not predictors for poor HRQOL. In conclusion, HRQOL for both right- and left-lobe donors in the long term (mean post-donation period, 6.8 years) was better than the Japanese norm population. However, the prolongation of symptoms or sequelae related to donation lowered mental health or social functioning. The emergence of co-morbidities after donation also significantly affected HRQOL in the long term. Careful follow-up and sustained counseling are required for donors with risk factors for lower HRQOL. Liver Transpl, 2012. © 2012 AASLD.
  Liver Transplantation 07/2012; · 3.39 Impact Factor
• Article: Efficacy of Ezetimibe is Associated with Gender and Baseline Lipid Levels in Patients with Type 2 Diabetes.

  Erina Shigematsu, Tadashi Yamakawa, Masataka Taguri, Satoshi Morita, Mikiya Tokui, Kazunori Miyamoto, Osamu Funae, Yoji Takatuka, Kazuaki Kadonosono, Hiroshi Shigematsu, Yasuo Terauchi
  [show abstract] [hide abstract]
  ABSTRACT: Aim: The combination of ezetimibe and a statin provides greater LDL-C reduction by inhibiting both intestinal cholesterol absorption and endogenous production of cholesterol. The present study was designed to examine the influence of ageing, gender, BMI, levels of LDL-C, and HbA1c on the response to ezetimibe add-on therapy.Methods: Patients who had been taking a statin for >3 months at the usual dose and whose LDL-C was >120 mg/dL were eligible for this study. Patients were assigned to receive add-on ezetimibe at 10 mg once daily for 12 weeks.Results: Adding ezetimibe to basal statin therapy resulted in a further 15.0% reduction of TC, 20.5% reduction of LDL-C, and 19.7% reduction of non-HDL-C. The change in TC was significantly greater in males than in females. The change in TG was significantly greater in patients with a baseline TG level ≥150 mg/dL. Multivariate regression analysis showed that male sex and LDL-C ≥140 mg/dL were independent predictors of TC reduction after adjustment for age, BMI, and HbA1c. A baseline TG ≥150 mg/dL was also an independent predictor of TG reduction.Conclusion: Addition of ezetimibe to ongoing statin therapy was effective in patients with type 2 diabetes. Male sex and baseline LDL-C levels are independent predictors of marked TC reduction by ezetimibe treatment.
  Journal of atherosclerosis and thrombosis 07/2012; 19(9):846-53. · 2.69 Impact Factor